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Abstract
Background: The success of the ‘‘war on cancer’’ initiated in 1971 continues to be debated, with trends in cancer mortality
variably presented as evidence of progress or failure. We examined temporal trends in death rates from all-cancer and the
19 most common cancers in the United States from 1970–2006.
Methodology/Principal Findings: We analyzed trends in age-standardized death rates (per 100,000) for all cancers
combined, the four most common cancers, and 15 other sites from 1970–2006 in the United States using joinpoint
regression model. The age-standardized death rate for all-cancers combined in men increased from 249.3 in 1970 to 279.8 in
1990, and then decreased to 221.1 in 2006, yielding a net decline of 21% and 11% from the 1990 and 1970 rates,
respectively. Similarly, the all-cancer death rate in women increased from 163.0 in 1970 to 175.3 in 1991 and then decreased
to 153.7 in 2006, a net decline of 12% and 6% from the 1991 and 1970 rates, respectively. These decreases since 1990/91
translate to preventing of 561,400 cancer deaths in men and 205,700 deaths in women. The decrease in death rates from all-
cancers involved all ages and racial/ethnic groups. Death rates decreased for 15 of the 19 cancer sites, including the four
major cancers, with lung, colorectum and prostate cancers in men and breast and colorectum cancers in women.
Conclusions/Significance: Progress in reducing cancer death rates is evident whether measured against baseline rates in
1970 or in 1990. The downturn in cancer death rates since 1990 result mostly from reductions in tobacco use, increased
screening allowing early detection of several cancers, and modest to large improvements in treatment for specific cancers.
Continued and increased investment in cancer prevention and control, access to high quality health care, and research
could accelerate this progress.
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Introduction
Temporal trends in death rates are the most reliable measure
of progress against cancer as they reflect improvements in
prevention, early detection and treatment. Although age-stan-
dardized cancer death rates in the U.S. have been decreasing since
the early 1990s [1,2,3,4], some reviewers cite limited improvement
in death rates as evidence that the ‘‘war on cancer’’, which was
initiated in 1971 by President Nixon’s administration, has failed
[5,6,7,8,9]. Many of these analyses fail to account for the
dominant and dramatic increase in cancer death rates due to
tobacco-related cancers in the latter part of the 20
th century.
Trends in cancer death rates in the U.S. and other industrialized
countries provide important insight into the factors associated with
economic development and Western lifestyles that drive cancer
rates upward as well as the most effective measures to counteract
these changes and reduce the cancer burden. In this paper, we
examine trends in death rates for all cancers combined and 19
common cancers from 1970–2006 and review the contribution of
prevention, early detection, and treatment to reducing cancer
death rates. We also provide estimates of the contribution of
specific cancer sites to the overall decline in death rates, the
number of deaths averted or postponed and the years of potential
life gained.
Methods
We obtained nationwide cancer mortality data for 1970 to 2006
from the SEER*Stat database [10], which defines major cancer
sites consistently over time in order to maximize comparability
across international classifications of diseases (ICD) versions and
facilitate reporting of long term mortality trends [11].
Death rates were directly age-standardized to the 2000 US
standard population for all cancers combined and 19 of the most
common cancers by using SEER*Stat software [12]. Use of the
2000 US standard population was adopted by Federal and private
public health agencies in 2002 to more accurately reflect the
contemporary mortality rates, given the aging of the U.S.
population [13]. For example, the age-adjusted rates for all
cancers combined and for the four major cancer sites in 2000 are
15%–50% higher when adjusted to the 2000 population standard
than to the 1970 standard [14].
Temporal trends from 1970 through 2006 for each cancer by
sex were described using joinpoint regression analysis (permutation
test) [15], which involves fitting a series of joined straight lines (a
maximum of four joinpoints) on a log scale to the trends in the
annual age-standardized rates [15]. The resultant trends of
varying time periods were described by annual percent change
(APC), i.e., the slope of the line segment (weighted least square
PLoS ONE | www.plosone.org 1 March 2010 | Volume 5 | Issue 3 | e9584regression, two-sided t test, P,0.05) [15]. Similarly, we examined
the trend in death rates with narrower intervals of attained age for
all cancers combined (20–49, 50–59, 60–69, 70–79, $80) and for
the four most common cancers (lung, colorectum, prostate, female
breast) (20–49, 50–64, $65). We also examined the trend in death
rates for all cancers combined and for the four major cancer sites by
age and race/ethnicity (whites, blacks, Indians/Alaska Natives [AI/
AN], Asian Pacific Islanders [API], Hispanics). For AI/AN, API,
and Hispanics, analyses were restricted to data from 1990–2006
because mortality data for these ethnic groups were not uniformly
availablebefore1990.Forlungcancer,weexaminedthe 5-yearage-
specific rates by year of birth beginning at age 30–34.
For cancer sites which had lower death rates in 2006 than in
1990/91 (the years when all-cancer death rates peaked in men and
women, respectively), we calculated the contribution of each
individual site to the total decrease in the overall cancer death
rates. We also estimated the total number of cancer deaths averted
due to the decline in the overall age-standardized cancer death
rates since the peak, in 1990 for males and 1991 for females, by
calculating the number of expected deaths in each calendar year
from 1990/91 through 2006 had the death rates not decreased.
This was done by multiplying the sex- and age-specific cancer
death rates in the peak year to the corresponding sex- and age-
specific populations, and then summing the difference between the
number of expected and observed deaths in each age group and
calendar year for men and for women separately over the 15 or 16
year interval. This method provides the net effect of both decreases
and increases death rates for specific cancer sites.
As additional measure for the impact of declining cancer death
rates on population health, we calculated years of potential life lost
(YPLL) due to cancer before age 75 for 2006 based on the
observed cancer deaths in 5-year age interval. We compared this
to the YPLL that would have been expected had the 1970 age-
specific cancer death rates continued to apply in 2006. YPLL gives
more weight to deaths occurring at younger ages [16].
Results
For all cancers combined, death rates (per 100,000) in men
increased from 249.3 in 1970 to 279.8 in 1990, and then decreased
to 221.1 in 2006 (Figure 1), yielding a relative decline of 21% and
11% from the 1990 (peak year) and 1970 (baseline) rates,
respectively. Similarly, the death rate from all-cancers combined
in women increased from 163.0 in 1970 to 175.3 in 1991, and then
decreased to 153.7 in 2006, a relative decline of 12% and 6% from
the 1991 (peak year) and 1970 rates, respectively. Reductions in
age-standardized death rates for all cancers combined since the
early 1990 were observed in each major racial and ethnic group,
although the onset and magnitude of the decreases vary (Figure 2,
Table S1). For example, compared to white women, the decrease
in AI/AN women was smaller and the decrease in Hispanic
women began later. Notably, black men and women still have
20%–50% excess overall cancer death rates compared to their
white counter parts, the group with the second highest mortality
rates. During the most recent time period (the last joinpoint
interval), rates also decreased in each age group, with the declines
beginning progressively earlier and becoming larger, in propor-
tionate terms, with decreasing age (Figure 3, Table S2).
Figure 4 shows trends in death rates for all races combined for
the four major cancer sites by sex and age. Rates decreased for
each major cancer site and age group, although the onset and
magnitude of reduction varies by sex and age, especially for lung
cancer (Table S3). Among men, lung cancer death rates continued
to decrease since 1990 in men, with the decreases beginning earlier
in younger ages. Among women, in contrast, the decreases in lung
cancer rates at each age were smaller and began much later. The
age-specific trends by year of birth show that lung cancer death
rates are decreasing among men and women born after the mid
1920s and 1930s, respectively (Figure S1). Similar to the trends for
all races combined, mortality trends for the four major cancer sites
(except for lung cancer in women) also decreased for each major
racial and ethnic group since the early 1990s, although the onset
and magnitude of reductions vary (Table S4). For example, the
Figure 1. Trends in age-standardized death rates for all cancers
combined by sex, 1970–2006. Dots represent observed rates and
solid lines fitted rates.
doi:10.1371/journal.pone.0009584.g001
Progress against Cancer
PLoS ONE | www.plosone.org 2 March 2010 | Volume 5 | Issue 3 | e9584average decrease in colorectal cancer death rates since 1990
was larger in whites than in most of the other racial and ethnic
groups.
Figure 5 shows trends in age-standardized death rates from
1970–2006 for 15 additional cancer sites by sex, with the APC
estimates given in Table S5. During the most recent time period,
death rates decreased for cancers of the oral cavity, stomach,
bladder, kidney, brain, and Non-Hodgkin lymphoma, and
leukemia in both males and females and for cancers of the
esophagus and ovary and melanoma and Hodgkin lymphoma in
females. In contrast, rates increased for esophagus cancer and
melanoma in men, liver cancer in both men and women, and
pancreas cancer in women. Death rates stabilized for pancreatic
cancer and Hodgkin lymphoma in men and for cervix and corpus
and uterus cancers in women. Notably, the 2006 death rates for
Hodgkin lymphoma in men, cervical cancer in women, and
stomach cancer in both men and women were less than one-third
of the 1970 rates. For the sites which increased during this time
interval, death rates nearly doubled for melanoma and liver cancer
in men and tripled for lung cancer in women. The downturn in
lung cancer death rates among women did not occur until 2002,
reversing the continuously increasing trend observed since
national compilation of vital statistics began in 1930s. It is
noteworthy that the largest absolute decreases in death rates (per
100,000) that occurred between 1990/91 and 2006 were observed
for lung cancer in men (23.2) and breast cancer in women (9.3).
These accounted for 37% of the total decrease in all-cancer death
rates in men and women during this time period (Table 1). The
decrease in prostate cancer death rates accounted for 24% of the
total decrease in men; reduction in colorectal cancer death rates
accounted for 17% and 23% of the total decrease in men and
women, respectively. Overall, the continued decrease in all-cancer
death rates from 1990–2006 in men and 1991–2006 in women
translates to averting of 561,400 cancer deaths in men and
205,700 cancer deaths in women that would have occurred if the
1990/91 rates were to prevail afterwards (Figure 6).
Cancer deaths in 2006 resulted in 4.4 million YPLL among
persons under age 75. If the 1970 age-specific death rates persisted
through 2006, the YPLL in 2006 would have been 6.4 million.
Thus, the decrease in cancer death rates in younger ages during
this 36 years time interval resulted in about 2.0 million years of
potential life gained under age 75 in the year 2006.
Figure 2. Trends in age-standardized all-cancer death rates by race/ethnicity, 1970–2006. AI/AN: American Indians and Alaska Natives;
API: Asian and Pacific Islanders. Dots represent observed rates and solid lines fitted rates.
doi:10.1371/journal.pone.0009584.g002
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Contrary to the pessimistic news from the popular media, overall
cancer death rates have decreased substantially in both men and
women whether measured against baseline rates in 1970/71 when
the National Cancer Act was signed by President Nixon or when
measured against the peak rates in 1990/91. The decrease involves
all age groups, all major racial and ethnic groups, and 15 of the 19
cancersitesconsideredinthisanalysis.Reductionsindeathratesfrom
the four major cancer sites (lung, female breast, prostate, colorectum)
accounted for about 60%–80% of the total decrease in all-cancer
death rates since 1990/91. The decrease in all-cancer death rates
since the peak years of 1990/91 translates to averting 561,400 cancer
deaths in men and 205,700 cancer deaths in women. Further, the
decrease in death rates at younger ages since 1970 resulted in about
2.0 million years of potential life gained under age 75 in 2006 alone.
Advances in prevention, early detection, and treatment all have
contributed to this progress in reducing death rates from cancer
[2,17,18,19,20]. The decreases in death rates from lung cancer
and other smoking-related cancers resulted mostly from reductions
in smoking prevalence since the 1950s [2,21]. Most of the
reduction in lung cancer death rates observed since in 1990 in men
and since in 2002 in women represents smoking cessation that
began among educated men and women in 1950s; the full benefits
of reduced initiation among adolescents will emerge in the future
as these generations age. Between 1965 and 2006, current smoking
prevalence among all U.S. adults 18 year and above decreased by
54% (from 51% to 24%) in men and by 46% (from 34% to 18%)
in women [22]. Despite these substantial reductions in smoking
prevalence and mortality from smoking-related cancers, cigarette
smoking still accounts for approximately 30% of all cancer deaths,
with lung cancer contributing most (80%) of these deaths [23].




PLoS ONE | www.plosone.org 4 March 2010 | Volume 5 | Issue 3 | e9584About 45 million adults continue to smoke cigarettes. Decreasing
initiation and increasing cessation through proven tobacco control
interventions continue to be important priorities for reducing
cancer mortality in the short and long term.
The dramatic decrease in stomach cancer death rates that has
occurred in most economically developed or transitioning
countries is thought to result from the combination of reduced
prevalence of Helicobacter Pylori infection and the benefits of
refrigeration [24,25]. The latter has reduced reliance on smoked
and salted preserved foods and increased the availability of fresh
fruits and vegetables. Since the early 1930s when national
mortality records became available, stomach cancer dropped
from the leading cause of cancer death to 11
th in men and from
2
nd to 12
th in women [26]. The decreases in mortality from female
breast cancer since 1989 and from colorectal cancer since the
1980s largely reflect a combination of earlier diagnosis through
screening and improved treatment [17,19,27]. In the case of
colorectal cancer, screening decreases incidence as well as
mortality rates through the detection and removal of precancerous
polyps [28]. Similarly, the large decrease in cervical cancer death
rates over the past 40–50 years resulted mostly from removal of
precancerous lesions through Pap smear screening beginning in
1950s [29,30]. However, rates have flattened in the three most
recent data years (2004–06), and it requires 2 or more additional
data years to ascertain this new pattern. Screening for breast
cancer for women beginning at age 40 and for colorectal cancer
for adults beginning at age 50 were introduced in early 1980s,
although national monitoring for these data did not begin until
1987 [31]. According to the most recent data from the National
Health Interview Survey, the percentage of women 50 or above
who had mammography in the past two years increased from 29%
in 1987 to 70% in 2000, and then slightly decreased to 67% in
2005 [32,33]. During the same time period, the percentage of
adults 50 or above who had screening for colorectal cancer
according to guideline increased from 27% to 47% [33,34].
The substantial decrease in prostate cancer death rates since the
mid 1990s thought to reflect improved treatment and the
introduction and wide dissemination of Prostate Specific Antigen
(PSA) blood test in men 50 or above since the late 1990s
[20,35,36,37]. However, a recent randomized trial in the U.S.
failed to demonstrate the benefit for PSA testing in reducing
deaths from prostate cancer, although another trail in Europe
Figure 4. Trends in age-standardized death rates (log scale) for major cancers by age, 1970–2006. Dots represent observed rates and
solid lines fitted rates.
doi:10.1371/journal.pone.0009584.g004
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have decreased substantially in many other western countries
where PSA testing is not widely practiced [40,41,42]. The increase
in prostate cancer death rates in late in 1980 in the U.S. thought to
reflect attribution bias [43]. The introduction and dissemination of
new treatments for Hodgkin lymphoma, leukemia, and testicular
cancer between 1950 and 1970 and for non-Hodgkin lymphoma
in the mid 1990s contributed to the rapid reductions in mortality
from these diseases [44,45,46,47,48].
In contrast to the long-term decreases in death rates for several
cancer sites, rates increased for cancers of the liver (both sexes),
esophagus (men), pancreas (women), and melanoma (men). The
increase in liver cancer is generally attributed to the increasing
prevalence of Hepatitis C infections [49], but may also be
influenced by rising obesity rates [50]. Both tobacco use and
obesity are thought to contribute to the long-term increase in
mortality from pancreas and esophagus cancers, but only the
obesity epidemic could contribute to the recent increases
[25,51,52,53]. Obesity increases gastroesophageal reflux disease,
the major risk factor for adenocarcinoma of the esophagus [54,55];
adenocarcinoma of the esophagus has been increasing for decades
[56]. The increase in melanoma death rates in men is generally
attributed to historical birth cohort trends in sun exposure [57].
The greater decrease in the overall cancer death rates in men
than women largely due to differences in mortality trends from
lung cancer which accounts for about 80% of all smoking
attributable cancer deaths and nearly 30% of the total cancer
deaths in the U.S. [21,58,59]. Lung cancer death rates have
continued to decrease since 1990 in men, while they continued to
increase through the mid 2000 in women. Trends in lung cancer
also explain, in part, why the decrease in overall cancer deaths
rates began earlier and were larger in proportionate terms in the
younger than in the older age groups. Smoking prevalence and
lung cancer peaked in those men born around 1920s and in
women born around the late 1930s, now in their 70–90s. Younger
cancer patients are also more likely to receive aggressive treatment
and to participate in clinical trials [17].
Racial/ethnic disparities in the reduction of overall or cancer-
specific death rates during the most recent time period reflect
differences in historical exposures to risk factors/and or access to
health care [4,19,60]. For example, the average decrease in
colorectal cancer death rates since 1990 appear to be larger among
Figure 5. Trends in age-standardized death rates for additional 15 select cancers, 1970–2006. Symbols represent observed rates and
solid lines fitted rates.
doi:10.1371/journal.pone.0009584.g005
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Death Rate Death Rate
per 100,000 per 100,000 Change Change % Contribution{
1990* 2006 Absolute %
Male
All Malignant Cancers 279.8 221.1 258.7 221.0
Decreasing
Lung & Bronchus 90.6 67.5 223.1 225.5 37.2
Prostate 38.6 23.6 215.0 238.9 24.2
Colorectum 30.8 20.5 210.3 233.4 16.5
Stomach 8.9 5.0 23.8 243.1 6.1
Oral Cavity & Pharynx 5.6 3.8 21.8 232.6 2.9
Non-Hodgkin Lymphoma 10.0 8.4 21.6 215.6 2.5
Leukemia 10.7 9.6 21.1 210.3 1.8
Brain & other nervous system 6.0 5.1 20.8 214.1 1.4
Larynx 3.0 2.2 20.8 226.2 1.3
Myeloma 4.8 4.4 20.5 29.7 0.8
Kidney & renal pelvis 6.2 5.7 20.4 26.9 0.7
Urinary bladder 8.0 7.6 20.4 25.0 0.6
Hodgkin Lymphoma 0.9 0.6 20.3 234.7 0.5
Other 39.8 37.6 22.2 25.6 3.6
Total 263.6 201.5 262.1 100.0
Increasing
Esophagus 7.2 7.9 0.7 9.7
Liver & Intrahepatic Bile duct 5.3 7.7 2.5 46.5
Melanoma of the Skin 3.8 4.1 0.3 7.1
Total 16.2 19.7 3.4
Death Rate Death Rate
per 100,000 per 100,000 Change Change % Contribution{
1991* 2006 Absolute %
Female
All Malignant Cancers 175.3 153.7 221.6 212.3
Decreasing
Breast 32.7 23.4 29.2 228.3 36.7
Colorectum 20.3 14.5 25.8 228.4 22.9
Non-Hodgkin Lymphoma 6.7 5.4 21.4 220.3 5.4
Stomach 4.0 2.6 21.4 234.0 5.4
Cervix Uteri 3.5 2.4 21.1 230.7 4.3
Ovary 9.5 8.5 21.0 210.2 3.9
Leukemia 6.3 5.4 20.9 214.6 3.7
Brain & other nervous system 4.1 3.4 20.7 217.6 2.9
Oral Cavity & Pharynx 2.0 1.4 20.6 231.6 2.5
Other 36.7 33.6 23.1 28.4 12.3
Total 125.9 100.7 225.2 220.0 100.0
Increasing
Lung & Bronchus 37.6 40.2 2.6 6.8
Liver & Intrahepatic Bile duct 2.5 3.3 0.8 30.0
Pancreas 9.3 9.5 0.2 2.1
Total 49.4 52.9 3.5
*Death rates from all cancer peaked in 1990 for men and 1991 for women.
{This calculation is based on each cancer site’s contribution to the increasing or decreasing portion of the total cancer death rate, depending on the individual site’s
trend; it does not represent the contribution to the net decrease in cancer death rates.
doi:10.1371/journal.pone.0009584.t001
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because whites have the highest colorectal screening rates of all
racial/ethnic groups [33], and white colorectal cancer patients are
more likely to receive the standard treatment [17,61].
Similar trends in death rates for most of the cancer sites
described here have been reported in several western countries.
For instance, lung cancer mortality rates among men continued to
decrease since at least the early 1990s in Several European
countries, Australia, and Canada [62,63,64] because as in the U.S.
the tobacco epidemic in men in these countries occurred before
the middle of the 20
th century [65]. Over the past 20 years, breast
cancer mortality trends have decreased in several Western
countries because of early detection through mammography,
improved treatment, and reduced use of post menopausal
hormone [66,67,68]. Remarkable decreases in cervical cancer
death rates have also been noted in several countries with long-
established cervical cancer screening programs, including Euro-
pean countries, Canada, and Australia [69,70,71].
The value of measuring temporal trends in death rates rather
than in relative survival is that death rates are much less
susceptible to artifactual changes from screening and lead time
or length bias. However, mortality trends may be affected by
changes in the quality of death certificates [72,73] and changes in
classification of causes of death [74]. Although the quality of cause
of death certification may have improved over the years, this is
unlikely to account for the large drops in mortality for either
specific cancer sites or all-cancers combined. No significant
discontinuities in the mortality trends occurred with the imple-
mentation of ICD-9 or ICD-10 for any of the cancer sites
considered in this analysis [75]. Further, any effect of the
introduction of revised ICD-coding on mortality trend is transient,
and should not affect long-term trends [74]. Another limitation of
our analysis is we presented data for broad racial and ethnic
groups only, and this may mask important differences in cancer
rates and trends by country of origin within each racial/ethnic
group. Among API women for example, cervical cancer rate
are almost three times as high in Vietnamese as in Chinese
or Japanese in part because Vietnamese women are recent
immigrants, are poorer, and have less access to cervical cancer
screening [76].
In addition to the steady reduction in mortality trends, basic and
clinical research has also contributed to better quality of life for
cancer survivors. These include relief from pain and other
distressing symptoms, sentinel lymph node biopsy for removal of
fewer regional lymph nodes, breast conserving surgery for patients
with breast cancer, limb sparing surgery for patients with sarcoma,
sphincter sparing surgery for patients with rectal cancer, and voice
preservation for patients with squamous cell of the head and neck
Figure 6. Total number of cancer deaths averted due to reduction in cancer death rates since 1990/1991. Solid lines represent observed
number of cancer deaths and dashes expected cancer deaths. Expected cancer deaths were based on had the peak rates in men (1990) and women
(1991) prevailed through 2006.
doi:10.1371/journal.pone.0009584.g006
Progress against Cancer
PLoS ONE | www.plosone.org 8 March 2010 | Volume 5 | Issue 3 | e9584cancers. Further, both chemo and radiation treatments have been
improved so that cancer cells are better targeted and adverse
health effects of healthy cells are minimized.
In summary, progress in reducing cancer death rates is evident
whether measured against baseline rates in 1970 or in 1990.
Downturns in overall cancer death rates since the early 1990s are
largely a result of tobacco control efforts beginning in the 1960s,
screening and early detection for several cancers disseminated in
the 1980s and 1990s, and modest to large improvements in
treatment and survival for specific cancers. Continued and
increased investment in cancer prevention and control programs,
access to high quality health care, and basic and clinical research
could accelerate this progress.
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